Reply to F. Liang et al

Affiliations

Comment

Jeffrey S Weber et al. J Clin Oncol. 2017.

. 2017 Jun 10;35(17):1968.

doi: 10.1200/JCO.2017.72.2645. Epub 2017 Mar 6.

¹ Jeffrey S. Weber, NYU Langone Medical Center, New York, NY; and Joel Jiang, Bristol-Myers Squibb, Princeton, NJ.

No abstract available

Comment on

Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma.
Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J, Sznol M, Long GV, Li H, Waxman IM, Jiang J, Robert C. Weber JS, et al. J Clin Oncol. 2017 Mar;35(7):785-792. doi: 10.1200/JCO.2015.66.1389. Epub 2016 Nov 14. J Clin Oncol. 2017. PMID: 28068177
Problematic Landmark Analysis Has Led to a Problematic Conclusion.
Liang F, Zhang S, Zhu J. Liang F, et al. J Clin Oncol. 2017 Jun 10;35(17):1967-1968. doi: 10.1200/JCO.2016.72.1290. Epub 2017 Mar 6. J Clin Oncol. 2017. PMID: 28591546 No abstract available.